Pelvic congestion needs attention in infertile women with Budd-Chiari syndrome

https://doi.org/10.1007/s12664-023-01341-z EDITORIAL Pelvic congestion needs attention in infertile women with Budd‑Chiari syndrome Anand Sharma1 · C. E. Eapen2 © Indian Society of Gastroenterology 2023 The advances in our understanding of the interplay between Budd-Chiari syndrome (BCS) and pregnancy have trans - lated into improved survival. Earlier reports documented BCS occurring in pregnant women as a sinister combination resulting in deaths in up to 50% of the mothers [ 1, 2]. It is indeed remarkable to note 100% maternal survival in recent reports of BCS in pregnancy (Table  1). Many of the reports of BCS in pregnancy are from India. The largest series of patients with BCS in pregnancy reported to date features in this issue of this journal [ 6]. The authors of this study document remarkable improve - ment in maternal survival with no complications related to pregnancy or liver disease in any of the study patients. The authors also did not find significant delay in diagnosis of BCS in their cohort, contrary to older studies of BCS patients [8]. It is likely that increasing awareness of this con- dition among clinicians, improved diagnostic modalities and appropriate treatments all have contributed to the excellent maternal survival now reported in these patients. BCS presenting as acute liver failure or acute-on-chronic liver failure is uncommon and has poorer outcomes. In a previous report from the same center, clinical presentation as acute-on-chronic liver failure was noted in 5% of BCS patients [9]. The current paper on BCS in pregnancy reports acute presentation of BCS in five out of the 121 (4%) study patients [6]. Endovascular therapies may improve survival in these uncommon presentations of BCS [ 9]. In contrast to the success achieved in maternal outcomes in pregnant women with BCS, fetal outcomes still remain sub-optimal (Table  1). In addition, infertility continues to be a problem in women with BCS. Primary infertility rates of 19.8% 6–25% 4 have been reported in women with BCS. Metabolic and hormonal alterations associated with liver dysfunction may contribute to infertility in women with chronic liver diseases. Another proposed mechanism of infertility or fetal losses in BCS may be pelvic congestion. Obstruction of inferior vena cava (IVC) resulting in congestion of pel - vic organs, evidenced by dilated pelvic veins, has been described [ 10]. An analogy to this hypothesis may be drawn from the link between IVC obstruction and vari - cocele, which is associated with male infertility. Surgery to correct varicocele improves male fertility by improving sperm count and quality [ 11]. One study reported 12 women in whom pelvic congestion syndrome was considered the only cause for infertility. Ovar- ian varices noted on transvaginal ultrasound or pelvic veno- gram were treated by endovascular means. Subsequently, eight out of the 12 women went on to become pregnant. All patients experienced complete or partial relief of pelvic pain. The authors concluded that embolization of ovarian varices is a safe and effective treatment in women with infertility linked to ovarian varices, who are trying to conceive [12]. A recent study has highlighted increased risk of new- onset heart failure with reduced left ventricular ejection fraction in infertile women [13]. However, congestive heart failure causing pelvic congestion, in turn contributing to infertility, has not been well studied. Chronic pelvic pain and presence of atypical varicose veins are features of pelvic congestion syndrome. Endovas- cular treatment is being considered for this condition [ 14]. Future studies need to focus on symptoms of pelvic con - gestion and imaging for varices in ovaries and other pelvic organs in patients with BCS who are infertile or have had prior pregnancy losses. Infertility caused by pelvic con - gestion may be expected to be seen more often in patients with BCS caused by obstruction at the level of IVC than of hepatic veins. Studies are needed to see if treatments to relieve pelvic congestion, if present, will help women with BCS who are infertile or have had prior fetal loss. * C. E. Eapen [email protected] 1 Department of Gastroenterology, All India Institute of Medical Sciences, Rishikesh 249 203, India 2 Department of Hepatology, Christian Medical College, Vellore, Tamil Nadu 632 004, India Indian Journal of Gastroenterology (January–February 2023) 42(1):14–16 Published online: 10 February 2023 1 3 Indian Journal of Gastroenterology (January–February 2023) 42(1):14–16 Hormonal pills are used to treat female infertility and their thrombogenic potential can also lead to exacerbation of underlying hepatic venous thrombosis in BCS [ 15]. The thrombophilic tendency associated with pregnancy may predispose to venous thromboembolism. In a study of 72 pregnant women, venous thromboembolism developed during the first trimester of pregnancy in 29 (40%) women, in the second trimester in 13 women (18%), and in the third trimester in 30 women (42%) [ 16]. A population- based study conducted over 30 years identified postpartum period as the time with maximal risk for venous throm - boembolism and pulmonary embolism during pregnancy [17]. Acute presentation of BCS during pregnancy is uncommon. Analysis of the clinical features (for exam - ple, is this more common in any particular trimester of pregnancy or in postpartum period) may improve our understanding of this uncommon presentation and lead to improved treatment outcomes. Being uncommon, multi- center studies are needed to address this issue. The use of oral anticoagulants in the first trimester of pregnancy raises the concern of fetal neural tube defects. Hence, low molecular weight heparin is recommended dur- ing the first trimester in women who need anticoagulation during pregnancy. As low molecular weight heparin is an expensive parenteral drug, many patients in resource-con - strained settings opt for oral anticoagulants to treat BCS during pregnancy. However, teratogenic effects of oral anti- coagulants are not predictable [ 18]. In conclusion, while the exciting advances achieved in treating BCS during pregnancy are laudable, there is scope for further improvement, especially of fetal outcomes in this scenario. Declarations Conflict of interest AS, and CEE declare no competing interests. Disclaimer The authors are solely responsible for the data and the con- tents of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, the Indian Society of Gastroenterology or the printer/ publishers are responsible for the results/findings and content of this article. References 1. Khuroo MS, Datta DV. Budd-Chiari syndrome following pregnancy. Report of 16 cases, with roentgenologic, hemodynamic and histologic studies of the hepatic outflow tract. Am J Med. 1980;68:113–21. 2. Dilawari JB, Bambery P, Chawla Y, et al. Hepatic outflow obstruc- tion (Budd-Chiari syndrome) experience with 177 patients and a review of the literature. Medicine (Baltimore). 1994;73:21–36. 3. Rautou PE, Angermayr B, Garcia-Pagan JC, et al. Pregnancy in women with known and treated Budd-Chiari syndrome: maternal and fetal outcomes. J Hepatol. 2009;51:47–54. 4. Shukla A, Sadalage A, Gupta D, et al. Pregnancy outcomes in women with Budd Chiari Syndrome before onset of symptoms and after treatment. Liver Int. 2018:754–9. 5. Khan F, Rowe I, Martin B, et al. Outcomes of pregnancy in patients with known Budd-Chiari syndrome. World J Hepatol. 2017;9:945–52. 6. Biswas S, Sheikh S, Vaishnav M, et al. Pregnancy outcomes in patients with Budd Chiari syndrome: A tertiary care experi - ence. Indian J Gastroenterol. 2023;42.  https:// doi. org/ 10. 1007/ s12664- 022- 01307-7. 7. Wiegers H, Hamulyák E, Damhuis S, et al. Pregnancy outcomes in women with Budd-Chiari syndrome or portal vein thrombosis – a multicentre retrospective cohort study. BJOG. 2022;129:608–17. 8. Sharma A, Goel A, Moses V, et al. Anticoagulating Budd-Chiari syndrome patients presenting with variceal bleed: a retrospective study. J Gastroenterol Hepatol. 2020;35:1397–1403. 9. Shalimar, Sharma S, Gamanagatti SR, et al. Acute on chronic liver failure in Budd Chiari syndrome: profile and predictors of outcome. Dig Dis Sci. 2020;65:2719–29. 10. Priyanka S, Parveen M, Unmesh S. Budd Chiari syndrome pre - senting as pelvic congestion syndrome : a rare case report. IOSR J Dent Med Sci. 2016;15:76–7. 11. Jensen CFS, Østergren P, Dupree JM, Ohl DA, Sønksen J, Fode M. Varicocele and male infertility. Nat Rev Urol. 2017;14:523–33. 12. Liu J, Han L, Han X. The effect of a subsequent pregnancy after ovarian vein embolization in patients with infertility caused by pelvic congestion syndrome. Acad Radiol. 2019;26:1373–7. Table 1 Some of the reported series of Budd-Chiari syndrome and pregnancy MTP medical termination of pregnancy Years of study Number of pregnant women enrolled Maternal survival Fetal outcome Reference no 1963–1978 16 50% Intrauterine death: 5 (including MTP: 3) [1] 1967–1991 38 48% Data not available [2] 1985–2005 16 100% < 20 weeks gestation: 7, stillbirth: 1 [3] 2012–2015 60 100% < 20 weeks: 59 (including MTP: 5), stillbirth: 10 [4] 2001–2015 7 100% < 20 weeks: 6 [5] 2017–2020 121 100% < 24 weeks: 16, stillbirth: 1, preterm: 5 [6] 2008–2021 12 100% < 24 weeks: 8 [7] 15 1 3 Indian Journal of Gastroenterology (January–February 2023) 42(1):14–16 13. Lau ES, Wang D, Roberts M, et al. Infertility and risk of heart failure in the Women’s Health Initiative. J Am Coll Cardiol. 2022;79:1594–603. 14. Bałabuszek K, Toborek M, Pietura R. Comprehensive overview of the venous disorder known as pelvic congestion syndrome. Ann Med. 2022;54:22–36. 15. Sharma A, Keshava SN, Eapen A, Elias E, Eapen CE. An update on the management of Budd-Chiari syndrome. Dig Dis Sci. 2021;66:1780–90. 16. Blanco-Molina A, Trujillo-Santos J, Criado J, et al. Venous throm- boembolism during pregnancy or postpartum: findings from the RIETE Registry. Thromb Haemost. 2007;97:186–90. 17. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3rd. Trends in the incidence of venous thromboembo- lism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143:697–706. 18. Dhillon SK, Edwards J, Wilkie J, Bungard TJ. High-versus low- dose warfarin-related teratogenicity: a case report and systematic review. J Obstet Gynaecol Can. 2018;40:1348–57 Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. 16 1 3